biostudies-literatureUnknown64Lassen Pp16-expression are implemented in the TNM8 classification of oropharyngeal cancer (OPSCC). Based on a nationwide cohort, we provide a detailed description of subsite variation in the age-standardised incidence-rates of OPSCC alongside an evaluation of the prognostic impact of p16-expression according to subsite after primary radiotherapy (RT). Patient/material and methods: A total of 8,462 Danish OPSCC patients from 1986 to 2020 were identified in the DAHANCA-database, and tumours were grouped into 'tonsil/base of tongue (BOT)', 'neighbouring subsites' and 'distant subsites'. Subsite-specific age-standardised incidence-rates were calculated, and outcome-analysis (loco-regional control, disease-free survival and overall-survival 5 years after the completion of RT) stratified by p16-status/sActa oncologica (Stockholm, Sweden)1071-1078https://www.ebi.ac.uk/biostudies/studies/S-EPMC12371743biostudies-literatureSubsite variation of HPV-related p16-expression in oropharynx cancer: Incidence and prognostic impact in a population-based DAHANCA cohort 1986-2020.PMC12371743Johansen JMaare CAndersen MPrimdahl HAlsner JPlaschke CCOvergaard JLassen PFarhadi MfalseSubsite variation of HPV-related p16-expression in oropharynx cancer: Incidence and prognostic impact in a population-based DAHANCA cohort 1986-2020.p16-expression are implemented in the TNM8 classification of oropharyngeal cancer (OPSCC). Based on a nationwide cohort, we provide a detailed description of subsite variation in the age-standardised incidence-rates of OPSCC alongside an evaluation of the prognostic impact of p16-expression according to subsite after primary radiotherapy (RT). Patient/material and methods: A total of 8,462 Danish OPSCC patients from 1986 to 2020 were identified in the DAHANCA-database, and tumours were grouped into 'tonsil/base of tongue (BOT)', 'neighbouring subsites' and 'distant subsites'. Subsite-specific age-standardised incidence-rates were calculated, and outcome-analysis (loco-regional control, disease-free survival and overall-survival 5 years after the completion of RT) stratified by p16-status/s2025-01-01T00:00:00Z2025 Aug2026-05-09T10:36:07.604Z2026-04-08T00:47:38.661ZS-EPMC123717434081424410.2340/1651-226X.2025.44027